RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential

Abstract N6‐methyladenosine (m6A), the newest and most prevalent layer of internal epigenetic modification in eukaryotic mRNA, has been demonstrated to play a critical role in cancer biology. Increasing evidence has highlighted that the interaction between cancer stem cells (CSCs) and the tumor immu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhihui Zhang, Chaoqi Zhang, Yuejun Luo, Guochao Zhang, Peng Wu, Nan Sun, Jie He
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	cancer stem cells immune checkpoint immunotherapy m6A modification metastasis recurrence Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/449aeb55239243a3a8c2cc0f06836d94
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:449aeb55239243a3a8c2cc0f06836d94
record_format	dspace
spelling	oai:doaj.org-article:449aeb55239243a3a8c2cc0f06836d942021-11-11T12:06:39ZRNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential2001-132610.1002/ctm2.525https://doaj.org/article/449aeb55239243a3a8c2cc0f06836d942021-09-01T00:00:00Zhttps://doi.org/10.1002/ctm2.525https://doaj.org/toc/2001-1326Abstract N6‐methyladenosine (m6A), the newest and most prevalent layer of internal epigenetic modification in eukaryotic mRNA, has been demonstrated to play a critical role in cancer biology. Increasing evidence has highlighted that the interaction between cancer stem cells (CSCs) and the tumor immune microenvironment (TIME) is the root cause of tumorigenesis, metastasis, therapy resistance, and recurrence. In recent studies, the m6A modification has been tightly linked to this CSC‐TIME interplay, participating in the regulation of CSCs and TIME remolding. Interestingly, the m6A modification has also been identified as a novel decisive factor in the efficacy of immunotherapies—particularly anti‐PD‐1/PD‐L1 monotherapies—by changing the plasticity of the TIME. Given the functional importance of the m6A modification in the crosstalk between CSCs and the TIME, targeting m6A regulators will open new avenues to overcome therapeutic resistance, especially for immune checkpoint‐based immunotherapy. In the present review, we summarize the current landscape of m6A modifications in CSCs and the TIME, and also prospect the underling role of m6A modifications at the crossroads of CSCs and the TIME for the first time. Additionally, to provide the possibility of modulating m6A modifications as an emerging therapeutic strategy, we also explore the burgeoning inhibitors and technologies targeting m6A regulators. Lastly, considering recent advances in m6A‐seq technologies and cancer drug development, we propose the future directions of m6A modification in clinical applications, which may not only help to improve individualized monitoring and therapy but also provide enhanced and durable responses in patients with insensitive tumors.Zhihui ZhangChaoqi ZhangYuejun LuoGuochao ZhangPeng WuNan SunJie HeWileyarticlecancer stem cellsimmune checkpointimmunotherapym6A modificationmetastasisrecurrenceMedicine (General)R5-920ENClinical and Translational Medicine, Vol 11, Iss 9, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer stem cells immune checkpoint immunotherapy m6A modification metastasis recurrence Medicine (General) R5-920
spellingShingle	cancer stem cells immune checkpoint immunotherapy m6A modification metastasis recurrence Medicine (General) R5-920 Zhihui Zhang Chaoqi Zhang Yuejun Luo Guochao Zhang Peng Wu Nan Sun Jie He RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
description	Abstract N6‐methyladenosine (m6A), the newest and most prevalent layer of internal epigenetic modification in eukaryotic mRNA, has been demonstrated to play a critical role in cancer biology. Increasing evidence has highlighted that the interaction between cancer stem cells (CSCs) and the tumor immune microenvironment (TIME) is the root cause of tumorigenesis, metastasis, therapy resistance, and recurrence. In recent studies, the m6A modification has been tightly linked to this CSC‐TIME interplay, participating in the regulation of CSCs and TIME remolding. Interestingly, the m6A modification has also been identified as a novel decisive factor in the efficacy of immunotherapies—particularly anti‐PD‐1/PD‐L1 monotherapies—by changing the plasticity of the TIME. Given the functional importance of the m6A modification in the crosstalk between CSCs and the TIME, targeting m6A regulators will open new avenues to overcome therapeutic resistance, especially for immune checkpoint‐based immunotherapy. In the present review, we summarize the current landscape of m6A modifications in CSCs and the TIME, and also prospect the underling role of m6A modifications at the crossroads of CSCs and the TIME for the first time. Additionally, to provide the possibility of modulating m6A modifications as an emerging therapeutic strategy, we also explore the burgeoning inhibitors and technologies targeting m6A regulators. Lastly, considering recent advances in m6A‐seq technologies and cancer drug development, we propose the future directions of m6A modification in clinical applications, which may not only help to improve individualized monitoring and therapy but also provide enhanced and durable responses in patients with insensitive tumors.
format	article
author	Zhihui Zhang Chaoqi Zhang Yuejun Luo Guochao Zhang Peng Wu Nan Sun Jie He
author_facet	Zhihui Zhang Chaoqi Zhang Yuejun Luo Guochao Zhang Peng Wu Nan Sun Jie He
author_sort	Zhihui Zhang
title	RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
title_short	RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
title_full	RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
title_fullStr	RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
title_full_unstemmed	RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
title_sort	rna n6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: current landscape and therapeutic potential
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/449aeb55239243a3a8c2cc0f06836d94
work_keys_str_mv	AT zhihuizhang rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT chaoqizhang rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT yuejunluo rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT guochaozhang rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT pengwu rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT nansun rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential AT jiehe rnan6methyladenosinemodificationinthelethalteamworkofcancerstemcellsandthetumorimmunemicroenvironmentcurrentlandscapeandtherapeuticpotential
_version_	1718439029456764928

RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential

Ejemplares similares